Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Mol Cancer Res. 2021 Apr 16;19(7):1137–1145. doi: 10.1158/1541-7786.MCR-21-0099

Figure 4: Constitutive overexpression of p65 inhibits the anti-tumour action of DMAPT alone or in combination with castration.

Figure 4:

Cell survival relative to untreated parental lines of (A) LNCaP-95 cells and (B) 22Rv1 cells overexpressing p65 cultured in 3D and treated for 72 hours ± DMAPT (5 μM) ± Enzalutamide (10 μM), (n = 10 3D spheres per treatment group, +/−1SEM). (C) Representative images of cell death staining in treated LNCaP-95. Dead and total cells in tumoroid cultures were stained using ReadyProbes™ Cell Viability Imaging Kit. * p<0.05, **p<0.01, ***p<0.001.